Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

SPIRIT IV, 2010 - everolimus ES vs paclitaxel ES

ISAR-DESIRE-2, 2010 - sirolimus ES vs paclitaxel ES

SORT-OUT-3, 2010 - zotarolimus ES vs sirolimus ES

RESOLUTE, 2010 - zotarolimus ES vs everolimus ES

Thiele, 2009 - sirolimus ES vs MIDCAB

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

ISAR TEST 3 (BP), 2009 - biodegradable-polymer sirolimus stent vs sirolimus ES

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

ENDEAVOR IV, 2009 - zotarolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

Juwana, 2009 - sirolimus ES vs paclitaxel ES

COMPARE, 2009 - everolimus ES vs paclitaxel ES

ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol ES vs zotarolimus ES

ZEST (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

BARI 2D, 2009 - CABG or PCI vs medical treatment

ZEST (vs SES), 2009 - zotarolimus ES vs sirolimus ES

ISAR-TEST-4, 2009 - sirolimus biodegradable polymer vs sirolimus ES

PASEO, 2009 - drug ES vs bare-metal stent

GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent

ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol ES vs sirolimus ES

ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus ES

SYNTAX, 2009 - paclitaxel ES vs CABG



See also:

  • All acute myocardial infarction clinical trials
  • All coronary artery disease clinical trials
  • All clinical trials of revascularization with drug eluting stent
  • All clinical trials of paclitaxel ES
    		•  

    HAAMU-STENT study, 2006

    unpublished (or not yet fully published) trial

    Treatments

    Studied treatment Taxus Express
    Control treatment Bare-metal-stent
    Concomittant treatment After PCI, patients were treated with a 300- to 600-mg loading dose of clopidogrel, followed by clopidogrel 75 mg daily for one year

    Patients

    Patients AMI - STEMI patients undergoing PCI
    Baseline characteristics
    age 63 
    diabetes (%) 15% 
    Lesion diameter inclusion criteria NA 
    Female (%) 28% 

    Method and design

    Randomized effectives 70 / 75 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 12 months
    Number of centre 1
    Geographic area Finland
    Primary endpoint none


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    8 / 70
         4 / 75
         classic 2,14 [0,67;6,80]

    Stent thrombosis (any, end of follow up)

    1 / 70
         3 / 75
         classic 0,36 [0,04;3,35]

    angiographic restenosis

    NA / 70
         NA / 75
         0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 8 / 70 (11,4%) 4 / 75 (5,3%) 2,14 [0,67;6,80]    
    Stent thrombosis (any, end of follow up) 1 / 70 (1,4%) 3 / 75 (4,0%) 0,36 [0,04;3,35]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 11,43% 5,33% 6,1%
    Stent thrombosis (any, end of follow up) 1,43% 4,00% -25,7‰


    Reference(s)

    unpublished (or not yet fully published) trial

    Trials register # NA
    • Tierala I, Syvaenne M, Kupari M. Randomised comparison of apaclitaxel-eluting and a bare metal stent in STEMI-PCI. TheHAAMU-STENT-study. Annual Scientifi c Meeting of theTranscatheter Cardiovascular Therapeutics; Washington, DC;Oct 2227, 2006. Abstract 178.
      Pubmed | Hubmed | Fulltext

    External links about this trial

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend